CARB-X加入联合国抗击抗菌素耐药性的全球努力

全球政府首脑 将利用多种机会在联合国大会上讨论解决抗菌素耐药性问题。

Presidents, prime ministers, and other heads of state gathering in New York this week for the annual UN General Assembly will turn their attention to a global public health initiative headquartered at BU Law: the 抗抗生素耐药细菌生物制药加速器 (CARB-X). CARB-X是一个3.5亿美元的跨大西洋合作伙伴关系，汇集了工业界、慈善机构、政府和学术界的领导人，旨在为未来25年重振抗微生物药物管线。

During a panel discussion on Tuesday, September 20, top-level government officials from the United Kingdom, the United States, Argentina, Australia, Kenya, Sweden, Japan, and South Africa will hear a presentation about CARB-X by Joseph Larsen, acting deputy director of the 生物医学高级澳门威尼斯人注册网站研究和开发局 (BARDA) within the HHS Office of the Assistant Secretary for Preparedness and Response. BARDA是CARB-X最大的资助者。

此外，这个由私营部门和非营利领导人组成的小组将讨论世界上12家最大的制药公司（包括所有仍在从事抗生素研发的大公司以及主要的仿制药公司）作出的一项重大新承诺，即采取具体澳门威尼斯人注册行动减少耐药性的发展和传播。

9月21日，联合国大会将在一次高级别会议上讨论抗微生物药物耐药性问题，届时全球政府首脑将承诺解决这一问题，并将批准一份详细的成果文件，处理一系列相关问题。

“This week the UN takes significant steps to reduce the health threat of antimicrobial resistance, with CARB-X as a key collaborator in the urgent global R&D effort,” says CARB-X Executive Director 凯文Outterson, professor of law and N. Neal Pike Scholar in Health and Disability Law at BU Law.